Advancing Best-In Class Weight Loss Therapies in the Evolving Obesity Landscape
The 3rd Obesity & Weight Loss Drug Development Summit is the place to be for experts in weight loss drug development tackling the obesity epidemic. This year, we're evaluating the obesity landscape, diving deep into the game-changing potential of novel targets and the latest GLP combination therapies to manage side effects and personalise patient treatment.
Hear from the titans of the pharmaceutical industry – Eli Lilly, Novo Nordisk, Boehringer Ingelheim as well as innovative biotechs including, Altimmune, High Tide Therapeutics, and iBio, and many more – as they share their groundbreaking research and strategies for developing more effective, tolerable, and long-lasting weight management solutions.
Obesity rates are increasing, and the pressure is on for real change. Don't miss this pivotal opportunity to network with 70+ obesity scientists and drug development experts forge collaborations, and be part of the solution. The future of weight loss treatment is being written now – be there!
World-Class Speaker Faculty Includes:
Testimonials:
“Great content and pace of the meeting to allow ample networking. Participants and speakers were super knowledgeable and engaged.”
Founder & Director, Mryacle
‘’The presentations were very informative, cutting edge and "timely", representing the current state of R&D in the Obesity field.’’
Chief Scientific Officer, Mitotherapeutix
“The quality of the speakers and the subject matter was outstanding. The attendees were very interactive, and discussions in the meeting and during the breaks were excellent.’’
Chief Scientific Officer, Cyta Therapeutics
Previously Attending Companies Include:
Partners
Want to Learn More? Download the Event Guide:
Other Events in this Series
